Ignite Creation Date:
2026-03-26 @ 3:20 PM
Ignite Modification Date:
2026-03-31 @ 12:08 PM
Study NCT ID:
NCT07474220
Status:
NOT_YET_RECRUITING
Last Update Posted:
2026-03-17
First Post:
2026-03-11
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Expression of SLC25A48 in Chronic Obstructive Pulmonary Disease
Sponsor:
Fu Jen Catholic University
Organization:
Study Overview
Official Title:
Association Between SLC25A48 Expression and Chronic Obstructive Pulmonary Disease Progression
Status:
NOT_YET_RECRUITING
Status Verified Date:
2026-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study aims to investigate the expression level of SLC25A48, a mitochondrial choline transporter, in peripheral blood mononuclear cells of patients with chronic obstructive pulmonary disease, and to analyze its correlation with inflammatory markers and choline metabolic byproducts.
Detailed Description:
Background:
Chronic obstructive pulmonary disease is the third leading cause of death worldwide, characterized by airflow limitation, alveolar damage, and chronic systemic inflammation. These features are closely associated with malnutrition, muscle loss, and oxidative stress. Mitochondrial dysfunction plays a critical role in immune dysregulation, with peripheral blood mononuclear cells widely used in studies on inflammation and metabolism. Choline, essential for one-carbon metabolism and immune function, requires specific transporters to enter mitochondria. SLC25A48, a newly identified mitochondrial choline transporter, is linked to impaired choline uptake, elevated reactive oxygen species, and metabolic imbalance. However, its role in chronic obstructive pulmonary disease remains unclear.
Study Design:
This multicenter, prospective observational study
Methods:
The expression of SLC25A48 in peripheral blood mononuclear cells will be quantified and analyzed in relation to inflammatory markers and choline metabolism indicators. All participants will undergo pulmonary function testing, nutritional and quality of life assessments, and blood biochemistry. Peripheral blood mononuclear cells will be isolated using density gradient centrifugation, followed by protein extraction and quantification via Western blot and image-based analysis.
Chronic obstructive pulmonary disease is the third leading cause of death worldwide, characterized by airflow limitation, alveolar damage, and chronic systemic inflammation. These features are closely associated with malnutrition, muscle loss, and oxidative stress. Mitochondrial dysfunction plays a critical role in immune dysregulation, with peripheral blood mononuclear cells widely used in studies on inflammation and metabolism. Choline, essential for one-carbon metabolism and immune function, requires specific transporters to enter mitochondria. SLC25A48, a newly identified mitochondrial choline transporter, is linked to impaired choline uptake, elevated reactive oxygen species, and metabolic imbalance. However, its role in chronic obstructive pulmonary disease remains unclear.
Study Design:
This multicenter, prospective observational study
Methods:
The expression of SLC25A48 in peripheral blood mononuclear cells will be quantified and analyzed in relation to inflammatory markers and choline metabolism indicators. All participants will undergo pulmonary function testing, nutritional and quality of life assessments, and blood biochemistry. Peripheral blood mononuclear cells will be isolated using density gradient centrifugation, followed by protein extraction and quantification via Western blot and image-based analysis.
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: